Tarsus Pharmaceuticals, Inc. (TARS) Misses Q2 EPS by 10c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.48), $0.10 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $102.7 million versus the consensus estimate of $95.68 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c